Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches
Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after delivery where infection can lead to sepsis, meningit...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2037350 |
| _version_ | 1797673265075847168 |
|---|---|
| author | Judith Absalon Raphael Simon David Radley Peter C. Giardina Kenneth Koury Kathrin U. Jansen Annaliesa S. Anderson |
| author_facet | Judith Absalon Raphael Simon David Radley Peter C. Giardina Kenneth Koury Kathrin U. Jansen Annaliesa S. Anderson |
| author_sort | Judith Absalon |
| collection | DOAJ |
| description | Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after delivery where infection can lead to sepsis, meningitis, pneumonia, or/and death. While intrapartum antibiotic prophylaxis (IAP) is the standard of care for prevention of invasive GBS disease in some countries, even in such settings a substantial residual burden of disease remains. A GBS vaccine administered during pregnancy could potentially address this important unmet medical need and provide an adjunct or alternative to IAP for the prevention of invasive GBS disease in neonates. A hurdle for vaccine development has been relatively low disease rates making efficacy studies difficult. Given the well-accepted inverse relationship between anti-GBS capsular polysaccharide antibody titers at birth and risk of disease, licensure using serological criteria as a surrogate biomarker represents a promising approach to accelerate the availability of a GBS vaccine. |
| first_indexed | 2024-03-11T21:42:01Z |
| format | Article |
| id | doaj.art-bb9a669cee1a4d8495518ab96bc7da63 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:01Z |
| publishDate | 2022-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-bb9a669cee1a4d8495518ab96bc7da632023-09-26T12:57:38ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-01-0118110.1080/21645515.2022.20373502037350Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approachesJudith Absalon0Raphael Simon1David Radley2Peter C. Giardina3Kenneth Koury4Kathrin U. Jansen5Annaliesa S. Anderson6Pfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentPfizer Vaccine Research & DevelopmentGroup B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after delivery where infection can lead to sepsis, meningitis, pneumonia, or/and death. While intrapartum antibiotic prophylaxis (IAP) is the standard of care for prevention of invasive GBS disease in some countries, even in such settings a substantial residual burden of disease remains. A GBS vaccine administered during pregnancy could potentially address this important unmet medical need and provide an adjunct or alternative to IAP for the prevention of invasive GBS disease in neonates. A hurdle for vaccine development has been relatively low disease rates making efficacy studies difficult. Given the well-accepted inverse relationship between anti-GBS capsular polysaccharide antibody titers at birth and risk of disease, licensure using serological criteria as a surrogate biomarker represents a promising approach to accelerate the availability of a GBS vaccine.http://dx.doi.org/10.1080/21645515.2022.2037350gbs;invasive disease;infants;iap;capsular polysaccharide;conjugate vaccine;maternal immunization;serocorrelate |
| spellingShingle | Judith Absalon Raphael Simon David Radley Peter C. Giardina Kenneth Koury Kathrin U. Jansen Annaliesa S. Anderson Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches Human Vaccines & Immunotherapeutics gbs;invasive disease;infants;iap;capsular polysaccharide;conjugate vaccine;maternal immunization;serocorrelate |
| title | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches |
| title_full | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches |
| title_fullStr | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches |
| title_full_unstemmed | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches |
| title_short | Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches |
| title_sort | advances towards licensure of a maternal vaccine for the prevention of invasive group b streptococcus disease in infants a discussion of different approaches |
| topic | gbs;invasive disease;infants;iap;capsular polysaccharide;conjugate vaccine;maternal immunization;serocorrelate |
| url | http://dx.doi.org/10.1080/21645515.2022.2037350 |
| work_keys_str_mv | AT judithabsalon advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT raphaelsimon advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT davidradley advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT petercgiardina advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT kennethkoury advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT kathrinujansen advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches AT annaliesasanderson advancestowardslicensureofamaternalvaccineforthepreventionofinvasivegroupbstreptococcusdiseaseininfantsadiscussionofdifferentapproaches |